MONTREAL, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (“Theratechnologies”), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its fourth quarter and full year fiscal 2022 ended November 30, on Tuesday, February 28, 2023.
The conference call will be held at 8:30 a.m. (ET) on February 28, 2023, to discuss the results and recent business updates. The call will be hosted by Paul Lévesque, President and Chief Executive Officer. Joining Mr. Lévesque on the call will be other members of the management team, including Chief Financial Officer Philippe Dubuc, Chief Medical Officer Christian Marsolais, and Chief Commercial Officer John Leasure, who will be available to answer questions from participants following prepared remarks.
Participants are encouraged to join the call at least ten minutes in advance to secure access.
Conference call dial-in and replay information is below:
| CONFERENCE CALL INFORMATION | |
| Conference Call Date: | February 28, 2023 |
| Conference Call Time: | 8:30 AM ET |
| North America Dial-in: | 1- 877-513-4119 |
| International Dial-in: | 1- 412-902-6615 |
| Access Code: | 2102918 |
| CONFERENCE CALL REPLAY | |
| North America Dial-in: | 1- 877-344-7529 |
| International Dial-in: | 1- 412-317-0088 |
| Replay Access Code: | 3648244 |
| Replay End Date | March 07, 2023 |
The live conference call will be accessible via webcast at:
https://edge.media-server.com/mmc/p/urf63wqf
About Theratechnologies
Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Further information about Theratechnologies is available on the Company's website at www.theratech.com, on SEDAR at www.sedar.com and on EDGAR at www.sec.gov.
Investor Inquiries:
Elif McDonald
Senior Director, Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.
1-438-315-8563
Media Inquiries:
Julie Schneiderman
Senior Director, Communications and Corporate Affaires
This email address is being protected from spambots. You need JavaScript enabled to view it.
1 514 336-7800
| Last Trade: | US$2.61 |
| Daily Change: | 0.02 0.77 |
| Daily Volume: | 242,822 |
| Market Cap: | US$120.010M |
April 09, 2025 April 08, 2025 March 12, 2025 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
